ClinicalTrials.gg
Sign In

Drug

LTX-315 clinical trials

Also written LTX-315.

studies test it
4
open now
1
in phase 3
0
first study started
2010

Keep track of what changes. Save the LTX-315 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

LTX-315
2
GV-1001
1

Combined with it in one product

LTX-315 + pembrolizumab
2
LTX-315 + ipilimumab
1
Arm C (Protocol version 6)
1
Arm D (Protocol version 6)
1

Studies by the year they started

4 studies that test it; most in 2010 (2)

Studies that test LTX-315, by start year
YearStudies
20102
20131
20241

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
1

What it is tested for

Each study’s main condition, where its own words name it.

Triple Negative Breast Neoplasms
1
Carcinoma
1
Melanoma
1

Who runs them

Industry 3 · Other 1

Lytix Biopharma AS (3) · Oslo University Hospital (1)

Often tested with

Tested in the same studies.

Pembrolizumab (2) · Ipilimumab (1)

Studies

Open first, then newest update. How each study uses LTX-315 is read from its arms, and is right about nine times in ten.

Testing it · 4

Codes

What other systems call LTX-315 · ClinicalTrials.gg INT000515

  • UNII (FDA) 75FBL12IZ7RUXOTEMITIDEConfirmed FDA, Wikidata
  • Wikidata Q27266383ltx-315Confirmed FDA, Wikidata
  • DrugBank DB12748One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.